"Receptors, Opioid, mu" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of opioid receptors recognized by its pharmacological profile. Mu opioid receptors bind, in decreasing order of affinity, endorphins, dynorphins, met-enkephalin, and leu-enkephalin. They have also been shown to be molecular receptors for morphine.
| Descriptor ID |
D017450
|
| MeSH Number(s) |
D12.776.543.750.695.620.550 D12.776.543.750.720.600.610.550 D12.776.543.750.750.555.610.550
|
| Concept/Terms |
Receptors, Opioid, mu- Receptors, Opioid, mu
- Opioid Receptors, mu
- mu Opioid Receptors
- Receptors, mu Opioid
- Receptors, mu
- mu Receptor
- Receptor, mu
- mu Receptors
- mu Opioid Receptor
- Opioid Receptor, mu
- Receptor, mu Opioid
Morphine Receptor- Morphine Receptor
- Receptor, Morphine
- Receptors, Morphine
- Morphine Receptors
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Opioid, mu".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, G-Protein-Coupled [D12.776.543.750.695]
- Receptors, Opioid [D12.776.543.750.695.620]
- Receptors, Opioid, mu [D12.776.543.750.695.620.550]
- Receptors, Neurotransmitter [D12.776.543.750.720]
- Receptors, Neuropeptide [D12.776.543.750.720.600]
- Receptors, Opioid [D12.776.543.750.720.600.610]
- Receptors, Opioid, mu [D12.776.543.750.720.600.610.550]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Neuropeptide [D12.776.543.750.750.555]
- Receptors, Opioid [D12.776.543.750.750.555.610]
- Receptors, Opioid, mu [D12.776.543.750.750.555.610.550]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Opioid, mu".
This graph shows the total number of publications written about "Receptors, Opioid, mu" by people in this website by year, and whether "Receptors, Opioid, mu" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1999 | 0 | 4 | 4 |
| 2001 | 2 | 1 | 3 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 1 | 2 |
| 2008 | 4 | 1 | 5 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 5 | 0 | 5 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Opioid, mu" by people in Profiles.
-
Wu B, Hand W, Alexov E. Opioid Addiction and Opioid Receptor Dimerization: Structural Modeling of the OPRD1 and OPRM1 Heterodimer and Its Signaling Pathways. Int J Mol Sci. 2021 Sep 24; 22(19).
-
Schacht JP, Hoffman M, Chen BH, Anton RF. Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial. Pharmacogenomics J. 2022 02; 22(1):1-8.
-
Anton RF, Voronin KE, Book SW, Latham PK, Randall PK, Glen WB, Hoffman M, Schacht JP. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial. Alcohol Clin Exp Res. 2020 10; 44(10):2084-2096.
-
Hartwell EE, Feinn R, Morris PE, Gelernter J, Krystal J, Arias AJ, Hoffman M, Petrakis I, Gueorguieva R, Schacht JP, Oslin D, Anton RF, Kranzler HR. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction. 2020 08; 115(8):1426-1437.
-
Hemby SE, McIntosh S, Leon F, Cutler SJ, McCurdy CR. Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addict Biol. 2019 09; 24(5):874-885.
-
Schacht JP, Randall PK, Latham PK, Voronin KE, Book SW, Myrick H, Anton RF. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status. Neuropsychopharmacology. 2017 Dec; 42(13):2640-2653.
-
Kupchik YM, Scofield MD, Rice KC, Cheng K, Roques BP, Kalivas PW. Cocaine dysregulates opioid gating of GABA neurotransmission in the ventral pallidum. J Neurosci. 2014 Jan 15; 34(3):1057-66.
-
Ray LA, Bujarski S, Squeglia LM, Ashenhurst JR, Anton RF. Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol. Alcohol Alcohol. 2014 May-Jun; 49(3):261-70.
-
Wong CJ, Witcher J, Mallinckrodt C, Dean RA, Anton RF, Chen Y, Fijal BA, Ouyang H, Dharia S, Sundseth SS, Schuh KJ, Kinon BJ. A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. Alcohol Clin Exp Res. 2014 Feb; 38(2):511-20.
-
Chaijale NN, Curtis AL, Wood SK, Zhang XY, Bhatnagar S, Reyes BA, Van Bockstaele EJ, Valentino RJ. Social stress engages opioid regulation of locus coeruleus norepinephrine neurons and induces a state of cellular and physical opiate dependence. Neuropsychopharmacology. 2013 Sep; 38(10):1833-43.